{"id":32514,"date":"2025-06-20T12:19:17","date_gmt":"2025-06-20T06:49:17","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32514"},"modified":"2026-04-30T11:54:42","modified_gmt":"2026-04-30T06:24:42","slug":"iga-nephropathy-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape","title":{"rendered":"Advancements in IgA Nephropathy (IgAN) Treatment: From Standard-of-care (SoC) to Emerging Therapies"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a07e10b8a228\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a07e10b8a228\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape\/#IgA_Nephropathy_IgAN_Pathogenesis_and_the_Need_for_Targeted_Therapies\" >IgA Nephropathy (IgAN): Pathogenesis and the Need for Targeted Therapies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape\/#Prevalence_and_Growth_Projections_for_IgA_Nephropathy\" >Prevalence and Growth Projections for IgA Nephropathy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape\/#Current_Therapeutic_Options_Navigating_the_IgA_Nephropathy_Treatment_Paradigm\" >Current Therapeutic Options: Navigating the IgA Nephropathy Treatment Paradigm<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape\/#Current_IgA_Nephropathy_Treatment_Market_Dynamics\" >Current IgA Nephropathy Treatment Market Dynamics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape\/#Critical_Gaps_in_IgA_Nephropathy_Management\" >Critical Gaps in IgA Nephropathy Management<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape\/#Innovative_Therapies_Reshaping_the_IgA_Nephropathy_Treatment_Landscape\" >Innovative Therapies Reshaping the IgA Nephropathy Treatment Landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape\/#Future_Outlook_of_IgAN_Treatment\" >Future Outlook of IgAN Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-iga-nephropathy-igan-pathogenesis-and-the-need-for-targeted-therapies\"><span class=\"ez-toc-section\" id=\"IgA_Nephropathy_IgAN_Pathogenesis_and_the_Need_for_Targeted_Therapies\"><\/span><strong>IgA Nephropathy (IgAN): Pathogenesis and the Need for Targeted Therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>IgA nephropathy is a complex autoimmune disorder characterized by the accumulation of galactose-deficient IgA1 antibodies in the glomeruli, triggering a cascade of immune responses that ultimately lead to chronic kidney damage. Driven by a multi-hit pathogenesis involving genetic predisposition, aberrant immune complex formation, and complement activation, the disease progresses silently until proteinuria and hematuria become clinically evident. Environmental triggers such as infections and hypertension further amplify renal injury, highlighting the need for early intervention. Despite advances in understanding its pathophysiology, the etiology remains elusive, underscoring the critical need for targeted therapies and personalized disease management strategies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-prevalence-and-growth-projections-for-iga-nephropathy\"><span class=\"ez-toc-section\" id=\"Prevalence_and_Growth_Projections_for_IgA_Nephropathy\"><\/span><strong>Prevalence and Growth Projections for IgA Nephropathy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>IgA nephropathy presents a steadily increasing burden across the major markets (the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan), with an estimated <strong>400K<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-epidemiology-forecast\">diagnosed prevalent cases of IgAN<\/a> in 2024, according to DelveInsight. Driven by improved diagnostic awareness and access to renal biopsy, the diagnosed population is expected to grow at a significant CAGR through 2034. The highest prevalence is observed in Japan, followed by the US and European markets. This epidemiological trend underscores the growing demand for targeted therapies and supports continued investment in innovative treatment approaches.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-therapeutic-options-navigating-the-iga-nephropathy-treatment-paradigm\"><span class=\"ez-toc-section\" id=\"Current_Therapeutic_Options_Navigating_the_IgA_Nephropathy_Treatment_Paradigm\"><\/span><strong>Current Therapeutic Options: Navigating the IgA Nephropathy Treatment Paradigm<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-market\">IgA nephropathy treatment landscape<\/a> is shifting towards more targeted and individualized care. While <strong>Angiotensin-Converting Enzyme (ACE)<\/strong> <strong>inhibitors<\/strong> and <strong>Angiotensin Receptor Blockers<\/strong> <strong>(ARB)<\/strong> remain the <strong>first-line<\/strong> for managing proteinuria and preserving renal function, newer agents like Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors and sparsentan offer added renal protection. Targeted-release budesonide marks a move toward precision therapies with reduced systemic side effects. In high-risk cases, corticosteroids and immunosuppressants like mycophenolate are used selectively due to safety concerns. Non-pharmacologic measures, including lifestyle modification and lipid management, remain essential. As IgA nephropathy becomes a chronically managed condition, balancing efficacy with safety is key to optimizing long-term outcomes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-iga-nephropathy-treatment-market-dynamics\"><span class=\"ez-toc-section\" id=\"Current_IgA_Nephropathy_Treatment_Market_Dynamics\"><\/span><strong>Current IgA Nephropathy Treatment Market Dynamics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The current IgA nephropathy market exhibits moderate competition, primarily dominated by small-molecule therapies, including Endothelin Type A Receptor (ETAR) antagonists, complement Factor B inhibitors, Angiotensin II Type 1 Receptor (AT1R) antagonists, and glucocorticoid receptor agonists. Notable products include <strong>VANRAFIA (atrasentan), FABHALTA (iptacopan), FILSPARI (sparsentan), <\/strong>and<strong> TARPEYO\/KINPEYGO (budesonide).<\/strong> While these agents reflect growing therapeutic options, the landscape remains open for innovation, especially with limited biologic presence, creating clear opportunities for emerging monoclonal antibodies to differentiate and expand treatment choices.<\/p>\n\n\n\n<p>FABHALTA and VANRAFIA, both developed by Novartis, represent targeted approaches to reshaping IgA nephropathy treatment. <a href=\"https:\/\/www.delveinsight.com\/blog\/fabhalta-for-igan-treatment\">FABHALTA<\/a>, an oral Factor B inhibitor, addresses complement-mediated kidney damage and is approved in the US to reduce proteinuria, with full approval pending Phase III outcomes. VANRAFIA, a highly selective ETAR antagonist acquired by Novartis through the acquisition of Chinook Therapeutics, also received accelerated US approval based on proteinuria reduction, with confirmatory data expected in early 2026. These therapies reflect Novartis\u2019 precision nephrology strategy by targeting distinct drivers of IgA nephropathy progression.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/filspari-for-iga-nephropathy\">FILSPARI<\/a> and TARPEYO\/KINPEYGO represent a major shift in the IgA nephropathy treatment paradigm by introducing targeted, nonimmunosuppressive oral therapies with global commercial reach. FILSPARI\u2019s dual blockade of endothelin-1 and angiotensin II offers a novel mechanism to preserve kidney function, positioning it as a potential long-term cornerstone treatment. Travere has partnered with CSL Vifor for European distribution and Renalys Pharma in Japan, where pivotal data from a registration-enabling study is anticipated in the second-half of 2025, underscoring its expanding global footprint.&nbsp;<\/p>\n\n\n\n<p>Similarly, TARPEYO\/KINPEYGO\u2019s gut-targeted delivery of budesonide addresses mucosal immune dysregulation at the source of IgA nephropathy, making it the first therapy to modify disease activity via the gut-kidney axis. In Japan, Viatris is developing it as NEFECON, with Phase III results expected in 2026. With established approvals and advancing pipelines across key regions, both therapies exemplify the shift toward precision medicine, reshaping clinical and commercial landscapes in IgA nephropathy.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/iga-nephropathy-igan-market\"><img decoding=\"async\" width=\"1024\" height=\"517\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30135901\/Key-Regulatory-Milestone-of-Approved-Therapies-1024x517.png\" alt=\"Key-Regulatory-Milestone-of-Approved-Therapies\" class=\"wp-image-32587\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30135901\/Key-Regulatory-Milestone-of-Approved-Therapies-1024x517.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30135901\/Key-Regulatory-Milestone-of-Approved-Therapies-300x151.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30135901\/Key-Regulatory-Milestone-of-Approved-Therapies-150x76.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30135901\/Key-Regulatory-Milestone-of-Approved-Therapies-768x388.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30135901\/Key-Regulatory-Milestone-of-Approved-Therapies-1536x775.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30135901\/Key-Regulatory-Milestone-of-Approved-Therapies-2048x1033.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>Additionally, the distribution through REMS (Risk Evaluation and Mitigation Strategy) Programs for FABHALTA and FILSPARI underscores the safety challenges inherent to their mechanisms of action and reflects a critical regulatory safeguard in IgA nephropathy treatment. FABHALTA\u2019s REMS focused on infection risk from encapsulated bacteria such as <em>Streptococcus pneumoniae<\/em>, <em>Neisseria meningitidis<\/em>, and <em>Haemophilus influenzae<\/em> <em>type b<\/em> due to complement inhibition, mandates pre-treatment vaccination and ongoing vigilance, particularly in immunologically vulnerable patients. FILSPARI\u2019s REMS, targeting hepatotoxicity and teratogenicity, imposes strict liver function monitoring and reproductive risk management. These measures, while clinically justified, introduce logistical burdens that can hinder prescriber adoption, delay treatment initiation, and restrict access in community settings.&nbsp;<\/p>\n\n\n\n<p>As a result, despite their therapeutic promise, REMS obligations temper the market penetration of both agents. From a strategic perspective, these programs highlight a broader trade-off: While enabling regulatory approval of high-risk, high-reward therapies, REMS can fragment access pathways and increase healthcare delivery complexity. Effective REMS navigation and provider education will, therefore, be essential to maximizing the real-world impact of these IgA nephropathy therapies.<\/p>\n\n\n\n<p>Among the currently <a href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-market\">approved IgAN therapies<\/a>, <strong>Novartis\u2019 VANRAFIA (atrasentan)<\/strong> is projected to become a blockbuster drug, with DelveInsight estimating revenues to <strong>exceed USD 1 billion <\/strong>by the mid-2030s. This projection reflects both strong commercial momentum and increasing clinical adoption. Notably, VANRAFIA can be easily integrated into existing supportive care regimens for IgA nephropathy, offering foundational therapy without the constraints of a REMS requirement, further boosting its accessibility and uptake. Moreover, strong insights from Key Opinion Leaders (KOLs) further validate the clinical potential and strategic value of these IgAN therapies.<\/p>\n\n\n\n<p>Despite recent advancements in IgA nephropathy treatment globally, Japan currently lacks approved therapies for the condition, creating a significant gap in the market. This absence presents an opportunity for companies to introduce innovative treatments, potentially addressing the unmet need in this region.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-critical-gaps-in-iga-nephropathy-management\"><span class=\"ez-toc-section\" id=\"Critical_Gaps_in_IgA_Nephropathy_Management\"><\/span><strong>Critical Gaps in IgA Nephropathy Management<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Despite therapeutic progress in IgA nephropathy, safety concerns remain a critical unmet need. Approved treatments, including corticosteroids, ETAR antagonist, and complement inhibitors, are often linked to serious adverse events, limiting their use in high-risk populations such as children and the elderly. These safety issues, compounded by the complexity of REMS programs and infection risks, hinder long-term adherence and the real-world utility of these programs. Additionally, the narrow clinical focus on renal endpoints overlooks the broader impact of comorbidities like hypertension, obesity, and dyslipidemia, which significantly influence disease progression. A shift toward integrated, patient-centered care, combining safer, targeted therapies with comprehensive metabolic and cardiovascular management, is essential for improving long-term outcomes in IgA nephropathy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-innovative-therapies-reshaping-the-iga-nephropathy-treatment-landscape\"><span class=\"ez-toc-section\" id=\"Innovative_Therapies_Reshaping_the_IgA_Nephropathy_Treatment_Landscape\"><\/span><strong>Innovative Therapies Reshaping the IgA Nephropathy Treatment Landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/blog\/4-late-stage-iga-nephropathy-treatment-drugs\">late-stage pipeline for IgA nephropathy<\/a> reflects a surge in innovation, with multiple assets in Phase III aiming to address key drivers of disease progression through targeted immunomodulation. IgAN drugs such as <strong>belimumab and siltuximab <\/strong>focus on B-lymphocyte stimulator (BLyS) inhibition, while<strong> atacicept and belimumab <\/strong>offer dual blockade of B-cell activating factor (BAFF) and B-lymphocyte stimulator (BLyS), aiming to suppress pathogenic B-cell activity. Meanwhile, <strong>sefaxersen<\/strong> employs antisense oligonucleotide technology to silence<strong> <\/strong>complement Factor B expression, and <strong>ULTOMIRIS<\/strong> targets terminal complement activation via C5 inhibition. These varied mechanisms mark a shift from symptomatic control toward disease-specific interventions.<\/p>\n\n\n\n<p>Several of these candidates are expected to enter the US market by 2034, with <strong>sibeprenlimab<\/strong> anticipated to lead the wave in 2025, followed by atacicept and povetacicept in 2026. Zigakibart and ULTOMIRIS may follow in 2027, while sefaxersen is projected for 2028. Collectively, these launches could significantly reshape the IgA nephropathy treatment landscape, offering more personalized, mechanism-based therapies that may improve long-term outcomes for patients with high-risk diseases.<\/p>\n\n\n\n<p>Additionally, a robust pipeline of early- and mid-stage assets is being explored for IgA nephropathy, including <strong>felzartamab, NM8074, ADX-097, WAL0921, KP104, ARO-C3, <\/strong>and<strong> TAK-079<\/strong>, among others. These candidates target various immune and complement pathways, further underscoring the expanding interest in disease-specific interventions aimed at modifying the underlying pathophysiology of IgA nephropathy.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/iga-nephropathy-igan-market\"><img decoding=\"async\" width=\"1024\" height=\"736\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140002\/Emerging-Assets-for-IgA-Nephropathy-1024x736.png\" alt=\"Emerging-Assets-for-IgA-Nephropathy\" class=\"wp-image-32589\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140002\/Emerging-Assets-for-IgA-Nephropathy-1024x736.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140002\/Emerging-Assets-for-IgA-Nephropathy-300x216.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140002\/Emerging-Assets-for-IgA-Nephropathy-150x108.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140002\/Emerging-Assets-for-IgA-Nephropathy-768x552.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140002\/Emerging-Assets-for-IgA-Nephropathy-1536x1103.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140002\/Emerging-Assets-for-IgA-Nephropathy-2048x1471.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>Among the <a href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-pipeline-insight\">emerging IgAN therapies<\/a>, atacicept and povetacicept are poised to become blockbuster treatments in the IgA nephropathy market; each projected to generate over<strong> USD 1 billion<\/strong> in revenue by the mid-2030s. These agents target key immunological drivers of the disease, <a href=\"https:\/\/www.delveinsight.com\/report-store\/baff-and-april-targeted-therapies-market-forecast\"><strong>BAFF<\/strong> and <strong>APRIL<\/strong><\/a>, offering a novel mechanism of action that directly addresses B-cell\u2013mediated pathogenesis. Clinical data show promising efficacy, with povetacicept demonstrating a 64% reduction in UPCR and atacicept achieving a 52% \u00b1 5% reduction, both with favorable safety profiles. Their advancement reflects a broader industry shift toward precision immunomodulation, highlighting their potential to redefine the future standard of care in IgA nephropathy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-outlook-of-igan-treatment\"><span class=\"ez-toc-section\" id=\"Future_Outlook_of_IgAN_Treatment\"><\/span><strong>Future Outlook of IgAN Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The projected IgA nephropathy market landscape in the major markets by 2034 reflects a transition from small molecule dominance to a more diversified therapeutic mix. Currently marketed agents, including VANRAFIA and FABHALTA, continue to hold a significant share; however, emerging biologics, such as atacicept and povetacicept, are expected to play a major role in shaping future treatment dynamics. Moreover, novel modalities and other therapies contribute smaller portions but represent ongoing innovation. This evolving distribution highlights the growing emphasis on targeted, disease-modifying therapies and suggests increasing competition, particularly as biologics gain momentum within a historically small molecule-driven market. For a visual depiction of this analysis, see the illustration below:<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/iga-nephropathy-igan-market\"><img decoding=\"async\" width=\"1024\" height=\"358\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140153\/Competitive-Analysis-of-IgAN-Market-Share-in-the-Major-Markets-in-2034-1024x358.png\" alt=\"Competitive-Analysis-of-IgAN-Market-Share-in-the-Major-Markets-in-2034\" class=\"wp-image-32590\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140153\/Competitive-Analysis-of-IgAN-Market-Share-in-the-Major-Markets-in-2034-1024x358.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140153\/Competitive-Analysis-of-IgAN-Market-Share-in-the-Major-Markets-in-2034-300x105.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140153\/Competitive-Analysis-of-IgAN-Market-Share-in-the-Major-Markets-in-2034-150x52.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140153\/Competitive-Analysis-of-IgAN-Market-Share-in-the-Major-Markets-in-2034-768x268.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140153\/Competitive-Analysis-of-IgAN-Market-Share-in-the-Major-Markets-in-2034-1536x537.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/30140153\/Competitive-Analysis-of-IgAN-Market-Share-in-the-Major-Markets-in-2034-2048x716.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>As IgA nephropathy continues to present therapeutic challenges, the treatment landscape is undergoing a meaningful shift with the rise of mechanism-driven therapies. While traditional IgAN treatments such as corticosteroids, RAAS blockers, and immunosuppressants remain foundational, emerging targeted agents are redefining the potential for disease modification. The growing <a href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-pipeline-insight\">IgAN pipeline<\/a>, especially with several candidates in late-stage development, reflects a strong push toward personalized and durable treatment options. Japan, with its high disease prevalence, stands out as a key market likely to benefit from these advances. However, clinical adoption will depend not only on efficacy but also on safety, tolerability, and patient adherence, critical factors in managing a chronic autoimmune condition. Regulatory hurdles, real-world data, and payer alignment will further shape the success of these new entrants. Ultimately, the evolving therapeutic landscape holds the promise of transforming IgA nephropathy from a disease with limited options to one with more precise and impactful treatment strategies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span>FAQs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1757481002385\"><strong class=\"schema-faq-question\"><strong>What factors are contributing to the increasing diagnosed population of IgAN?<\/strong><\/strong> <p class=\"schema-faq-answer\">IgA nephropathy presents a steadily increasing burden across the leading markets (the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan), with an estimated 400K diagnosed prevalent cases of IgAN in 2024, according to DelveInsight. Driven by improved diagnostic awareness and access to renal biopsy, the diagnosed population is expected to grow at a significant CAGR through 2034.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757481011466\"><strong class=\"schema-faq-question\"><strong>What are the FDA-approved drugs for IgAN available in the market?<\/strong><\/strong> <p class=\"schema-faq-answer\">The current IgA nephropathy market exhibits moderate competition, primarily dominated by small-molecule therapies, including Endothelin Type A Receptor (ETAR) antagonists, complement Factor B inhibitors, Angiotensin II Type 1 Receptor (AT1R) antagonists, and glucocorticoid receptor agonists. Notable approved IgAN drugs include VANRAFIA (atrasentan), FABHALTA (iptacopan), FILSPARI (sparsentan), and TARPEYO\/KINPEYGO (budesonide).<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757481025375\"><strong class=\"schema-faq-question\"><strong>What are some key IgAN drugs to watch?<\/strong><\/strong> <p class=\"schema-faq-answer\">Emerging IgAN drugs in clinical trials include Atrasentan, Sibeprenlimab (VIS-649), Zigakibart (BION-1301), IONIS-FB-LRx\/RG6299, Povetacicept, ULTOMIRIS (ravulizumab), Atacicept (VT-001), Felzartamab, and others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757481036891\"><strong class=\"schema-faq-question\"><strong>Where is the IgAN market headed?<\/strong><\/strong> <p class=\"schema-faq-answer\">The IgAN market size in the 7MM was valued at ~USD 730 million in 2024 and is anticipated to grow with a significant CAGR of 30.5% during the study period (2020-2034).<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>IgA Nephropathy (IgAN): Pathogenesis and the Need for Targeted Therapies IgA nephropathy is a complex autoimmune disorder characterized by the accumulation of galactose-deficient IgA1 antibodies in the glomeruli, triggering a cascade of immune responses that ultimately lead to chronic kidney damage. Driven by a multi-hit pathogenesis involving genetic predisposition, aberrant immune complex formation, and complement [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":32517,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22236,22274,18841,18839,18840,18838,18877,22206,22235],"industry":[17225],"therapeutic_areas":[17230,17227],"class_list":["post-32514","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-fabhalta","tag-filspari","tag-iga-nephropathy","tag-iga-nephropathy-drug-pipeline","tag-iga-nephropathy-epidemiology","tag-iga-nephropathy-market","tag-iga-nephropathy-pipeline","tag-igan","tag-igan-treatment","industry-pharmaceutical","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Charting the Future of IgA Nephropathy Treatment<\/title>\n<meta name=\"description\" content=\"IgA nephropathy treatment market landscape by 2034 reflects a transition from small molecule dominance to a more diversified therapeutic mix.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Charting the Future of IgA Nephropathy Treatment\" \/>\n<meta property=\"og:description\" content=\"IgA nephropathy treatment market landscape by 2034 reflects a transition from small molecule dominance to a more diversified therapeutic mix.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-20T06:49:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-30T06:24:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/20121631\/iga-nephropathy-treatment-landscape.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Charting the Future of IgA Nephropathy Treatment","description":"IgA nephropathy treatment market landscape by 2034 reflects a transition from small molecule dominance to a more diversified therapeutic mix.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"Charting the Future of IgA Nephropathy Treatment","og_description":"IgA nephropathy treatment market landscape by 2034 reflects a transition from small molecule dominance to a more diversified therapeutic mix.","og_url":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-06-20T06:49:17+00:00","article_modified_time":"2026-04-30T06:24:42+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/20121631\/iga-nephropathy-treatment-landscape.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape","name":"Charting the Future of IgA Nephropathy Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/20121631\/iga-nephropathy-treatment-landscape.png","datePublished":"2025-06-20T06:49:17+00:00","dateModified":"2026-04-30T06:24:42+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"IgA nephropathy treatment market landscape by 2034 reflects a transition from small molecule dominance to a more diversified therapeutic mix.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#faq-question-1757481002385"},{"@id":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#faq-question-1757481011466"},{"@id":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#faq-question-1757481025375"},{"@id":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#faq-question-1757481036891"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/20121631\/iga-nephropathy-treatment-landscape.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/20121631\/iga-nephropathy-treatment-landscape.png","width":466,"height":284,"caption":"iga-nephropathy-treatment-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#faq-question-1757481002385","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#faq-question-1757481002385","name":"What factors are contributing to the increasing diagnosed population of IgAN?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"IgA nephropathy presents a steadily increasing burden across the leading markets (the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan), with an estimated 400K diagnosed prevalent cases of IgAN in 2024, according to DelveInsight. Driven by improved diagnostic awareness and access to renal biopsy, the diagnosed population is expected to grow at a significant CAGR through 2034.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#faq-question-1757481011466","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#faq-question-1757481011466","name":"What are the FDA-approved drugs for IgAN available in the market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The current IgA nephropathy market exhibits moderate competition, primarily dominated by small-molecule therapies, including Endothelin Type A Receptor (ETAR) antagonists, complement Factor B inhibitors, Angiotensin II Type 1 Receptor (AT1R) antagonists, and glucocorticoid receptor agonists. Notable approved IgAN drugs include VANRAFIA (atrasentan), FABHALTA (iptacopan), FILSPARI (sparsentan), and TARPEYO\/KINPEYGO (budesonide).","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#faq-question-1757481025375","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#faq-question-1757481025375","name":"What are some key IgAN drugs to watch?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Emerging IgAN drugs in clinical trials include Atrasentan, Sibeprenlimab (VIS-649), Zigakibart (BION-1301), IONIS-FB-LRx\/RG6299, Povetacicept, ULTOMIRIS (ravulizumab), Atacicept (VT-001), Felzartamab, and others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#faq-question-1757481036891","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape#faq-question-1757481036891","name":"Where is the IgAN market headed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The IgAN market size in the 7MM was valued at ~USD 730 million in 2024 and is anticipated to grow with a significant CAGR of 30.5% during the study period (2020-2034).","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/20121631\/iga-nephropathy-treatment-landscape-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FABHALTA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FILSPARI<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgA Nephropathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgA Nephropathy Drug Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgA Nephropathy Epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgA Nephropathy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgA Nephropathy Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgAN<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgAN treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">FABHALTA<\/span>","<span class=\"advgb-post-tax-term\">FILSPARI<\/span>","<span class=\"advgb-post-tax-term\">IgA Nephropathy<\/span>","<span class=\"advgb-post-tax-term\">IgA Nephropathy Drug Pipeline<\/span>","<span class=\"advgb-post-tax-term\">IgA Nephropathy Epidemiology<\/span>","<span class=\"advgb-post-tax-term\">IgA Nephropathy Market<\/span>","<span class=\"advgb-post-tax-term\">IgA Nephropathy Pipeline<\/span>","<span class=\"advgb-post-tax-term\">IgAN<\/span>","<span class=\"advgb-post-tax-term\">IgAN treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 months ago","modified":"Updated 2 weeks ago"},"absolute_dates":{"created":"Posted on Jun 20, 2025","modified":"Updated on Apr 30, 2026"},"absolute_dates_time":{"created":"Posted on Jun 20, 2025 12:19 pm","modified":"Updated on Apr 30, 2026 11:54 am"},"featured_img_caption":"iga-nephropathy-treatment-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32514"}],"version-history":[{"count":5,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32514\/revisions"}],"predecessor-version":[{"id":35114,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32514\/revisions\/35114"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32517"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32514"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32514"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}